Top 10 Stocks to Watch — Wednesday, August 19
Moderna surges 80%+ on FDA approval, Keysight beats by 24%, and the Iran blockade reshapes the energy and defense setup. Here are the 10 names worth watching today — with watch levels, trigger setups, and the afternoon FOMC catalyst mapped out.
The pre-market session on Wednesday, August 19, belongs to one name: Moderna, surging more than 80% after the FDA signed off on its updated mRNA COVID-19 vaccine. But beneath that headline, the broader setup is more nuanced — S&P 500 futures are barely changed, two diverging macro forces are in play, and the most consequential market event today happens not at the open but at 2:00 p.m. ET, when the Federal Reserve releases minutes from its July 28–29 meeting. Those minutes could clarify whether the three dissenting Fed hawks who wanted a rate hike were outliers or a preview.
Geopolitics remains the other weight on the session. President Trump ruled out Iran talks, and Strait of Hormuz transit volumes have collapsed — only five cargo ships passed through on Saturday versus 31 the prior weekend, a 90% drop since hostilities began. The IEA has slashed its 2026 global supply forecast accordingly, with Brent holding near $91.55 and WTI at $84.61. That backdrop is doing real work for energy and defense names. Asian markets are broadly weaker, with South Korea's KOSPI off more than 5%, a reminder that the global risk appetite is not fully settled heading into the U.S. open.
The watchlist below reflects all three threads — a biotech breakout with genuine regulatory backing, a post-earnings AI instruments trade, a defense sector with a fresh price target upgrade, and a cluster of energy names with structural FCF support at current crude prices. The paywall entries include the specific watch levels, trigger setups, and the three lower-profile names — including a profitable small-cap biotech and a defense MRO play trading at a significant valuation discount to peers — where most of today's asymmetric setups sit.
1. Moderna (MRNA) — $115.66 pre-market (+83.70%)
The catalyst is layered and real. The FDA approved Moderna's updated COVID-19 vaccine targeting the LP.8.1 variant on August 19, layered on top of the August 5–6 approval of mFLUSIVA — the company's mRNA-based influenza vaccine for adults 50 and older, the first mRNA flu vaccine ever cleared by the FDA. For a company that spent the better part of 18 months re-establishing its post-COVID narrative, this is a platform validation moment: the mRNA delivery system now has two approved commercial vaccines across two disease categories.
The stock is entering historically extended territory intraday — an 83% pre-market surge demands caution on chasing. But the nature of the move matters. This is not a trial readout or a rumor; it is a regulatory decision on a named product with commercial supply already staged for the 2026–27 respiratory season. Prior to this morning, MRNA had already gained approximately 130% year-to-date. A consolidation into the $100–$110 band after the open would represent a more structured entry for those watching the long-term platform thesis rather than the day-one spike.
Watch for: First-hour volume and any post-open consolidation above $100. A hold above the prior week's high with volume normalization is the trigger for sustained follow-through.
2. Northrop Grumman (NOC) — $587.16 pre-market (+2.97%)
On August 17, Citi raised its price target on Northrop Grumman to $667, and the rationale is structural, not cyclical: the proposed $1.5 trillion U.S. defense budget for 2027 and the ongoing Iran conflict are creating a sustained procurement cycle for advanced systems. Northrop's footprint — B-21 Raider strategic bomber, Space Systems for advanced satellite reconnaissance, and hypersonic weapons — aligns directly with what the Pentagon is prioritizing in a near-peer conflict environment.
The $667 target from Citi implies roughly 14% upside from Friday's close. More important than the target is the direction: Northrop has underperformed Lockheed Martin and RTX Corp on a 2026 year-to-date basis, which analysts note makes it the more compelling risk-adjusted entry in the defense trio with the most direct Iran theater exposure still ahead in terms of procurement follow-through.
Watch for: A break above $595 on volume, which would clear the August high and open the $620–$630 range as the next test. Watch the FOMC minutes at 2pm — defense names are not rate-sensitive, which makes them a natural hedge into today's minutes release.
3. Keysight Technologies (KEYS) — $351.40 pre-market (+3%)
Keysight reported fiscal Q3 results on August 18 and beat on both lines by margins that caught the Street off guard. Adjusted EPS of $3.07 vs. the $2.48 consensus — a 24% beat — and revenue of $1.85 billion vs. $1.74 billion expected. The driver is unambiguous: Communications Solutions Group revenue grew 43% year-over-year as demand for AI data center testing equipment accelerated. Keysight makes the instruments that hyperscalers and chipmakers use to validate high-speed interconnects, optical networks, and next-generation memory interfaces at 800G and 1.6T speeds. As AI infrastructure spending enters its next buildout phase, Keysight is at the measurement layer — the tollbooth that every component must pass through before it ships.
Full-year guidance was raised to $7.1 billion in revenue (vs. $6.9 billion prior consensus) and EPS of $11.46 (vs. $10.00 prior consensus). Despite the beat, the stock dropped 7% on the day of the report before recovering overnight. Today's 3% pre-market move reflects the market working through that initial sell-the-news reaction.
Watch for: $355 as the level to clear, which represents the pre-earnings resistance. A sustained move through that level with volume opens the $370–$380 range based on the raised guidance multiple.
The rest of this briefing is for paid members: watch levels and trigger setups for entries 4–10, the specific small-cap biotech with $101.9M quarterly revenue trading at a fraction of its revenue multiple, the defense MRO name at a 28% P/E discount to its sector average, and the E&P upstream play generating exceptional free cash flow at current WTI — plus the bottom-line positioning framework for the FOMC minutes at 2pm.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.